Latest ACC/AHA Treatment Guidelines For Heart Failure Recommend CHF Solutions' Ultrafiltration Therapy

Main Category: Heart Disease
Also Included In: Cardiovascular / Cardiology
Article Date: 16 Apr 2009 - 5:00 PDT

email to a friend   printer friendly   opinions  

CHF Solutions announced today that in the latest update of the guidelines for the diagnosis and management of heart failure in adults, ultrafiltration is now a Class IIa recommendation and a Level of Evidence of B.

The new recommendation states "Ultrafiltration is reasonable for patients with refractory congestion not responding to medical therapy" and in the defined classification scheme, translates to "recommendation in favor of treatment or procedure being useful/effective."

Aquapheresis™, CHF Solutions' simplified and unique form of ultrafiltration, is now ranked higher in the Level of Evidence than the standard and common secondary treatments, such as salt restriction, strict I/Os, higher doses of loop diuretics, addition of a second diuretic, continuous infusion of a loop diuretic, vasodilators, and IV inotropes. All of these are Level of Evidence C.

"These updates reflect the growing understanding and acceptance of Aquapheresis' evidence-based medicine," said David Springer, president and chief executive officer of CHF Solutions. "With proven benefits to patients and savings from length of stay and rehospitalization reductions, these guideline updates will enable the millions of patients suffering from fluid overload due to heart failure to have better access to all effective treatment options."

CHF Solutions' Aquapheresis therapy is a method to safely and effectively remove the excess salt and water in patients with fluid overload. Currently, Aquapheresis is available in over 200 medical centers and outpatient clinics worldwide. To date, more than 20,000 patients have received this therapy.

About the 2009 ACCF/AHA Guidelines Focused Update

The focused guideline updates incorporate new clinical trial evidence, mostly from presentations at meetings of the ACC, AHA, and European Society of Cardiology since the last update in 2005. The document, 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults, was created and endorsed by the American College of Cardiology Foundation, the American Heart Association Task Force on Practice Guidelines, and the International Society for Heart and Lung Transplantation. For more information, visit here.

About CHF Solutions, Inc.

CHF Solutions, based in Brooklyn Park, Minn., is a privately held manufacturer of medical devices for cardiac care. The company's mission is to provide medical practitioners with innovative and practical solutions that enable the treatment of patients with unmet clinical needs. For more clinical and corporate information, go here.

Source
CHF Solutions, Inc

• Additional
• References
• Citations